5 Biotech Stocks to Buy Today According to Kerr Neilson’s Platinum Asset Management

2. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Platinum Asset Management’s Stake Value: $24.7 million

Percentage of Platinum Asset Management’s 13F Portfolio: 0.68%

Number of Hedge Fund Holders: 14

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is an all purpose company that combines various disciplines such as biology, chemistry, data analytics, and others to create treatments for diseases such as colitis, ovarian cancer, gangliosidosis, lung cancers, and more.

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) reported -$0.38 in GAAP EPS for its fourth fiscal quarter alongside revenue of $2.55 million. Following the earnings results, BofA slashed its stock rating to Neutral from Buy and kept a $10 price target for the company.

Mr. Neilson’s hedge fund had owned 1.4 million Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) shares during the three months ending in December 2021. Insider Monkey’s fourth quarter of 2021 survey of 924 hedge funds listed down 14 as having bought a stake in the company.

Benjamin A. Smith’s Laurion Capital Management is Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)’s largest investor. It owns a $67 million stake that comes via 3.9 million shares.